UK phase three trials of the experimental Novavax COVID-19 vaccine have found it demonstrated 89.3% efficacy against the virus.
Preliminary analysis showed the new UK variant was detected in more than half of the coronavirus cases recorded in the trials, with the vaccine candidate shown to be 95.6% effective against the original strain and 85.6% effective against the variant.
The study involved more than 15,000 participants aged 18 to 84, with 27% aged over 65.
Prime minister Boris Johnson called the result "good news".
"Our medicines regulator will now assess the vaccine, which will be made in Teesside. If approved, we have 60 million doses on order," he said.